東方生物(688298.SH)業績快報:2020年度淨利潤升1956.37%至16.88億元
格隆匯 2 月 26日丨東方生物(688298.SH)披露2020年度業績快報,實現營業總收入32.62億元,同比增長787.92%;歸屬於母公司所有者的淨利潤16.88億元,同比增長1956.37%;歸屬於母公司所有者的扣除非經常性損益的淨利潤16.70億元,同比增長2096.27%;基本每股收益14.07元。
2020年度,全球範圍內爆發新冠疫情,公司積極響應新冠檢測產品需求,全力支持疫情防控事業,快速開發了新型冠狀病毒(2019-nCoV) IgM/IgG 抗體檢測試劑盒(膠體金法)、新型冠狀病毒2019-nCoV 核酸檢測試劑盒(熒光PCR法)、新型冠狀病毒抗原快速檢測試紙(膠體金法)、甲乙型流感及新型冠狀病毒抗原聯合檢測試紙(膠體金法)、甲乙型流感/新型冠狀病毒/呼吸道合胞病毒/腺病毒抗原聯合檢測試劑等系列新冠檢測產品,並結合公司自身競爭優勢和產能匹配能力,上半年重點推動了新型冠狀病毒(2019-nCoV) IgM/IgG抗體檢測試劑盒(膠體金法)市場化,下半年重點推動了新型冠狀病毒抗原快速檢測試紙(膠體金法)市場化,均取得了重大銷售業績突破,促使公司2020年度整體經營業績呈現大幅度增長。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.